{"prompt": "['IRB Approved', 'Document Release Date: 02/26/2020', 'CC Protocol Number: 9582', 'PI: Michael T. Schweizer, MD', 'Apalutamide in Active Surveillance patients', 'Protocol Version: 6.0; September 06, 2019', 'Probable-The adverse event is most likely related to the investigational', 'agent(s).', 'Definite- The adverse event is clearly related to the investigational agent(s).', 'Based on this information, a decision will be made whether an adverse event should be', 'reported as an expedited report (Serious Adverse Event, section 3.0) in addition to the', 'routinely reported clinical data. Expedited adverse event reports that meet Institutional', 'reporting criteria should be submitted to the Institutional Review Board (IRB) in', \"accordance with policies of the coordinating center's IRB and local IRB where\", 'applicable (for the participating sites), and to the FDA in accordance with regulations', 'under 21 CFR 312.32. Additionally, all SAEs should be submitted to Janssen Scientific', 'Affairs, LLC within 24 hours of becoming aware of event and via secure e-mail.', '9.6.3. Documenting Adverse Events', 'Each individual sign or symptom must be documented separately. Worksheets', 'must be signed and dated by person conducting evaluation to be used as source', 'documentation. The attribution of all adverse events must be verified by an', 'investigator. Evaluation of laboratory toxicities may be documented directly on a', 'printed laboratory report or CRF provided it is signed by the investigator.', 'However, if an action was conducted due to this abnormality (e.g., RBC', 'transfusion due to low Hgb) this would be recorded on the AE form also.', 'Recording should be done in a concise manner using standard, acceptable', 'medical terms.', 'The adverse event recorded should not be a procedure or a clinical', 'measurement (i.e., a laboratory value or vital sign) but should reflect the reason', 'for the procedure or the diagnosis based on the abnormal measurement.', 'Preexisting conditions that worsen in severity or frequency during the Study', 'should also be recorded (a preexisting condition that does not worsen is not an', 'adverse event).', 'Further, a procedure or surgery is not an adverse event; rather, the event leading', 'to the procedure or surgery is considered an adverse event. Any event requiring', '65', 'Printed on 1/29/2021']['IRB Approved', 'Document Release Date: 02/26/2020', 'CC Protocol Number: 9582', 'PI: Michael T. Schweizer, MD', 'Apalutamide in Active Surveillance patients', 'Protocol Version: 6.0; September 06, 2019', \"in-patient hospitalization that occurs during the course of a subject's participation\", 'in a trial must be reported as an SAE. Hospitalizations that do not meet the', 'criteria for SAE reporting are:', 'A. Reasons described in the Protocol, e.g. drug administration, Protocol-', 'required testing', 'B. Surgery or procedure planned prior to entry into the Study.', \"If, in the Sponsor Investigator's judgment, a clinically significant worsening from\", 'baseline is observed in any laboratory or other test parameter (e.g.,', 'electrocardiogram [ECG], angiogram), physical exam finding, or vital sign, a', 'corresponding clinical adverse event should be recorded.', 'If a specific medical diagnosis has been made, that diagnosis or syndrome', 'should be recorded as the adverse event, whenever possible. However, a', 'complete description of the signs, symptoms and investigations which led to the', 'diagnosis should be provided. For example, if clinically significant elevations of', 'liver function tests are known to be secondary to hepatitis, \"hepatitis\" and not', '\"elevated liver function tests\" should be recorded. If the cause is not known, the', 'abnormal test or finding should be recorded as an adverse event, using', 'appropriate medical terminology (e.g., thrombocytopenia, peripheral edema, QT', 'prolongation).', '9.6.4. Maintenance of Safety Information', 'All safety data should be maintained in a research database in a retrievable', 'format. The Principal Investigator shall provide all adverse events, both serious', 'and non-serious, in report format. However, in certain circumstances more', 'frequent provision of safety data may be necessary (e.g., to fulfill a regulatory', 'request, and as such the data shall be made available within a reasonable', \"timeframe at Janssen Scientific Affairs' request).\", '66', 'Printed on 1/29/2021']\n\n###\n\n", "completion": "END"}